EMA401 is used in the treatment of chronic pain conditions, particularly neuropathic pain. It acts as a selective angiotensin II type 2 receptor (AT2R) antagonist, which helps reduce pain signaling in the peripheral nervous system. This makes it a promising candidate for patients who do not respond well to conventional pain medications. It has been investigated in clinical trials for conditions such as postherpetic neuralgia and painful diabetic neuropathy. Because it does not act on the central nervous system in the same way as opioids, EMA401 offers pain relief without the risk of addiction or significant central side effects. Its development represents a novel approach to managing chronic pain through peripheral receptor modulation.